# A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease

> **NCT06413511** · PHASE1 · WITHDRAWN · sponsor: **GlaxoSmithKline**

## Conditions studied

- Autoimmune Diseases

## Interventions

- **BIOLOGICAL:** Belantamab

## Key facts

- **NCT ID:** NCT06413511
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-06-03
- **Primary completion:** 2025-07-08
- **Final completion:** 2025-07-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06413511

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06413511, "A Study to Investigate the Safety and Pharmacological Effect of a Single Intravenous Infusion of Belantamab in Male and Female Participants Aged 18 to 75 With Autoimmune Disease". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT06413511. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*